source
- Jaguar LAA acquires Johnson & Johnson's Laminar atrial fibrillation device assetsJaguar LAA, a newly formed medtech company, announced it has purchased assets related to Johnson & Johnson's Laminar atrial fibrillation device program. The Laminar technology is a catheter‑based…
- AstraZeneca’s Etcamah fails Phase 3 trial, dashing hopes for $2.9 billion breast cancer marketAstraZeneca’s oral selective estrogen receptor degrader Etcamah was evaluated in the Phase 3 SERENA-4 trial as a first-line option for patients with ER-positive, HER2-negative advanced breast cance…